PFE logo

Pfizer (PFE)

Profile

Full Name

Pfizer Inc.

Ticker Symbol

PFE

Exchange

NYSE

Sector

Healthcare

Industry

Drug Manufacturers - General

Country

United States

IPO

June 1, 1972

Indexes

S&P 500

Website

http://www.pfizer.com

Employees

81000

Key Details

Price

$21.59(-4.00%)

Market cap

$122.36B(Mega cap)

Last Dividend

$0.43

TTM Dividend yield

7.83%

Annual revenue

$63.63B(+6.84% YoY)

Annual EPS

$1.41(+281.08% YoY)

PE ratio

15.31

Next earnings date

Apr 29, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$21.59
PFE price is $21.59

30-Day Relative Volume

1.00
PFE 30-day relative volume is 1.00

Price Performance

Price Today change

-4%
PFE price is down -4% today

Price YTD change

-18.62%
PFE price is down -18.62% since January 1st

Price 1-year change

-17.97%
PFE price is down -17.97% year-on-year

Price 3-year change

-60.87%
PFE price is down -60.87% over the past 3 years

Price Range

Price All-time high

$61.71
PFE price is currently -65.01% below its historical high of $61.71

Price 3-year low

$20.92
PFE price is currently +3.20% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$122.36B
PFE market capitalization is $122.36 billion

Market cap 3-year change

-60.33%
PFE market capitalization is down -60.33% over the past 3 years

Market cap All-time high

$343.79B
PFE market capitalization is currently -64.41% below its historical high of $343.79 billion

Market cap sector rank

98.6%
PFE market capitalization is higher than 98.6% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+0.01%
PFE shares outstanding is up +0.01% year-on-year

Shares Outstanding 3-Year Change

+1.37%
PFE shares outstanding is up +1.37% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.34
PFE beta is 0.34

200-day SMA

$27.35
PFE price is currently -21.05% below its 200-day simple moving average

50-day SMA

$25.53
PFE price is currently -15.44% below its 50-day simple moving average

RSI

24.11
PFE 14-day relative strength index is 24.11

Volume

1.00
PFE 30-day relative volume is 1.00

ATR

$0.88
PFE average true range is $0.88

10-day Historical Volatility

41.82%
PFE 10-day historical volatility is 41.82%

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Last Paid Dividend

$0.43
PFE last dividend was $0.43 per share, with an ex-dividend date of January 24, 2025

Next Dividend

-
PFE next dividend has not yet been announced

Dividend per share

Dividend per share

$1.68
PFE annual dividend per share is $1.68

Dividend per share Sector Rank

61.63%
PFE annual dividend per share is higher than 61.63% of companies in Healthcare sector

Dividend per share 1-Year Change

+2.44%
PFE annual dividend per share is up +2.44% year-on-year

Dividend per share 3-Year Change

+7.69%
PFE annual dividend per share is up +7.69% over the past 3 years

Dividend yield

Dividend yield

7.78%
PFE annual dividend yield is 7.78%

Dividend yield Sector Rank

89.41%
PFE annual dividend yield is higher than 89.41% of companies in Healthcare sector

Other

Payout ratio

118.44%
PFE annual payout ratio is 118.44%

Dividends paid

$9.51B
PFE annual dividends paid is $9.51 billion

Free cash flow

$9.84B
PFE annual free cash flow is $9.84 billion

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$63.63B
PFE annual revenue is $63.63 billion

Revenue Analysts estimate

$62.96B
PFE annual revenue is currently +1.07% higher than the consensus analysts' forecast

Revenue 1-year change

+6.84%
PFE annual revenue is up +6.84% year-on-year

Revenue Sector rank

98.54%
PFE annual revenue is higher than 98.54% of companies in Healthcare sector

EPS

EPS

$1.41
PFE annual earnings per share is $1.41

EPS Analysts estimate

$2.95
PFE annual earnings per share is currently -52.20% lower than the consensus analysts' forecast

EPS 1-year change

+281.08%
PFE annual earnings per share is up +281.08% year-on-year

EPS Sector rank

90.67%
PFE annual earnings per share is higher than 90.67% of companies in Healthcare sector

Profit

Gross profit

$45.78B
PFE annual gross profit is $45.78 billion

Gross margin

71.94%
PFE annual gross profit margin is 71.94%

Operating profit

$14.94B
PFE annual operating income is $14.94 billion

Operating margin

23.48%
PFE annual operating profit margin is 23.48%

Net income

$8.03B
PFE annual net profit is $8.03 billion

Net margin

12.62%
PFE annual net profit margin is 12.62%

Expenses

Total expenses

$48.69B
PFE annual total expenses is $48.69 billion

Operating expenses

$30.84B
PFE annual total operating expenses is $30.84 billion

Cost of goods sold

$17.85B
PFE annual cost of goods sold is $17.85 billion

Selling, general & administrative expenses

$14.73B
PFE annual SGA is $14.73 billion

Depreciation and amortization

$7.01B
PFE annual depreciation & amortization is $7.01 billion

Interest expense

$3.09B
PFE annual interest expense is $3.09 billion

Income tax

-$28.00M
PFE annual income tax is -$28.00 million

EBIT & EBITDA

EBIT

$11.11B
PFE annual earnings before interest & taxes is $11.11 billion

EBITDA

$16.40B
PFE annual EBITDA is $16.40 billion

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$213.40B
PFE annual total assets is $213.40 billion

Non current assets

$163.04B
PFE annual long term assets is $163.04 billion

Current assets

$50.36B
PFE annual total current assets is $50.36 billion

Cash and cash equivalents

$1.04B
PFE annual cash & cash equivalents is $1.04 billion

Accounts receivable

$11.46B
PFE annual accounts receivable is $11.46 billion

Inventory

$10.85B
PFE annual inventory is $10.85 billion

Liabilities

Total liabilities

$124.90B
PFE annual total liabilities is $124.90 billion

Long term liabilities

$81.90B
PFE annual total long term liabilities is $81.90 billion

Current liabilities

$42.99B
PFE annual total current liabilities is $42.99 billion

Accounts payable

$5.63B
PFE annual accounts payable is $5.63 billion

Debt

Total debt

$63.65B
PFE annual total debt is $63.65 billion

Total debt 1-year change

-10.16%
PFE annual total debt is down -10.16% year-on-year

Long term debt

$56.70B
PFE annual long term debt is $56.70 billion

Short term debt

$6.95B
PFE annual short term debt is $6.95 billion

Equity & Capital

Shareholders equity

$88.20B
PFE annual stockholders equity is $88.20 billion

Book value

$88.20B
PFE annual book value is $88.20 billion

Retained earnings

$116.72B
PFE annual retained earnings is $116.72 billion

Working capital

$7.36B
PFE annual working capital is $7.36 billion

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$12.74B
PFE annual cash flow from operations is $12.74 billion

Cash from operations 1-year change

+46.48%
PFE annual cash flow from operations is up +46.48% year-on-year

Cash from investing

$2.65B
PFE annual cash flow from investing activities is $2.65 billion

Cash from investing 1-year change

+108.22%
PFE annual cash flow from investing activities is up +108.22% year-on-year

Cash from financing

-$17.14B
PFE annual cash flow from financing activities is -$17.14 billion

Cash from financing 1-year change

-165.76%
PFE annual cash flow from financing activities is down -165.76% year-on-year

CAPEX

CAPEX

$2.91B
PFE annual capital expenditures is $2.91 billion

CAPEX 1-year change

-25.54%
PFE annual capital expenditures is down -25.54% year-on-year

Free Cash Flow

Free cash flow

$9.84B
PFE annual free cash flow is $9.84 billion

Free cash flow 1-year change

+105.2%
PFE annual free cash flow is up +105.2% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

71.94%
PFE annual gross profit margin is 71.94%

Operating margin

23.48%
PFE annual operating profit margin is 23.48%

Net margin

12.62%
PFE annual net profit margin is 12.62%

ROA & ROE

ROA

3.65%
PFE annual return on assets is 3.65%

ROE

9.03%
PFE annual return on equity is 9.03%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

15.31
PFE price to earnings ratio is 15.31

PE ratio Sector rank

28.43%
PFE price to earnings ratio is higher than 28.43% of companies in Healthcare sector

PB Ratio

PB ratio

1.39
PFE price to book ratio is 1.39

PB ratio Sector rank

53.95%
PFE price to book ratio is higher than 53.95% of companies in Healthcare sector

PS Ratio

PS ratio

1.92
PFE price to sales ratio is 1.92

PS ratio Sector rank

43.59%
PFE price to sales ratio is higher than 43.59% of companies in Healthcare sector

Enterprise value

Enterprise value

$184.96B
PFE enterprise value is $184.96 billion

Enterprise value Sector rank

99.18%
PFE enterprise value is higher than 99.18% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

10.45
PFE EV/EBITDA is 10.45

EV/EBITDA Sector rank

83.07%
PFE EV/EBITDA is higher than 83.07% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

1.17
PFE annual current ratio is 1.17

Quick ratio

0.92
PFE annual quick ratio is 0.92

Leverage

Debt to equity

0.72
PFE annual debt to equity ratio is 0.72

Interest coverage ratio

3.60
PFE annual interest coverage ratio is 3.60

Risk & Stability

Piotroski F-Score

8
PFE piotroski f-score is 8

Altman Z-Score

1.87
PFE altman z-score is 1.87

Analyst ratings

Recent major analysts updates

Mar 18, 25 Guggenheim
Buy
Mar 12, 25 Guggenheim
Buy
Feb 10, 25 Guggenheim
Buy
Feb 5, 25 UBS
Neutral
Jan 28, 25 Citigroup
Neutral
Jan 8, 25 UBS
Neutral
Dec 18, 24 Truist Securities
Buy
Dec 11, 24 Guggenheim
Buy
Nov 15, 24 Wolfe Research
Underperform
Oct 30, 24 Morgan Stanley
Equal-Weight

Institutional Ownership

Similar stocks

SNY logo
Sanofi (SNY)
VRTX logo
Vertex Pharmaceuticals Incorporated (VRTX)
GILD logo
Gilead Sciences (GILD)
DHR logo
Danaher (DHR)
SYK logo
Stryker (SYK)
BSX logo
Boston Scientific (BSX)
MDT logo
Medtronic (MDT)
BMY logo
Bristol-Myers Squibb (BMY)
ELV logo
Elevance Health (ELV)
  • What is the ticker symbol for Pfizer?
  • Does Pfizer pay dividends?
  • What sector is Pfizer in?
  • What industry is Pfizer in?
  • What country is Pfizer based in?
  • When did Pfizer go public?
  • Is Pfizer in the S&P 500?
  • Is Pfizer in the NASDAQ 100?
  • Is Pfizer in the Dow Jones?
  • When was Pfizer's last earnings report?
  • When does Pfizer report earnings?
  • Should I buy Pfizer stock now?

What is the ticker symbol for Pfizer?

The ticker symbol for Pfizer is NYSE:PFE

Does Pfizer pay dividends?

Yes, Pfizer pays dividends. The last payment was $0.43, with an ex-dividend date on January 24, 2025

What sector is Pfizer in?

Pfizer is in the Healthcare sector

What industry is Pfizer in?

Pfizer is in the Drug Manufacturers - General industry

What country is Pfizer based in?

Pfizer is headquartered in United States

When did Pfizer go public?

Pfizer's initial public offering (IPO) was on June 1, 1972

Is Pfizer in the S&P 500?

Yes, Pfizer is included in the S&P 500 index

Is Pfizer in the NASDAQ 100?

No, Pfizer is not included in the NASDAQ 100 index

Is Pfizer in the Dow Jones?

No, Pfizer is not included in the Dow Jones index

When was Pfizer's last earnings report?

Pfizer's most recent earnings report was on Feb 4, 2025

When does Pfizer report earnings?

The next expected earnings date for Pfizer is Apr 29, 2025

Should I buy Pfizer stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page